Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,363
Recruiting: 3,965
Ph III recruiting: 535
Growth YoY: +10.3%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,404)

clinicaltrialsPublishedShowing 1,051–1,080 of 1,080 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04807673	Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002)	recruiting	Phase 3	342	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Jun 1, 2022	clinicaltrials
NCT05388500	Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C)	not yet recruiting	Phase 3	800	Institut de cancérologie Strasbourg Europe